Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men ≥ 21 years of age with a life expectancy estimated to be \> 10-years.~* Diagnosis of adenocarcinoma of the prostate confirmed by MSKCC or participating site pathology review.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Prostate cancer clinical stage T1c-T2a~* PSA \< 10ng/mL (this will be the PSA level prompting the prostate biopsy)~* MRI evidence of one-sided disease performed within 3 months of registration~* Prostate size \<60 cc at time of treatment- if the prostate is larger, hormonal therapy is allowed to achieve the required size Screening biopsy parameters:~* Minimum of 10 biopsy cores~* Gleason grade 7 in two cores or less, with no primary Gleason grade 4 or 5 in any cores~* Unilateral cancer (only right-sided or left-sided, not bilateral)~* No more than 50 % cancer in any one biopsy core~* No more than 25 % of cores containing cancer~* Repeat transrectal or transperineal prostate biopsy that must meet the following parameters:~* Minimum of 12 biopsy cores~* Unilateral cancer (only right-sided or left-sided, not bilateral)~* Gleason grade 7 in two cores or less, with no primary Gleason grade 4 or 5 in any cores~* No more than 50 % cancer in any one biopsy core~* No more than 25 % of cores containing cancer~Subject Exclusion Criteria:~* Medically unfit for anesthesia~* Evidence or suspicion of extracapsular extension on MRI~* IPSS score \> 18~* Unable to receive MRI~* Prior radiotherapy for the current disease

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prostate Biopsy, Focal Brachytherapy , Assessment of QOL (Type: EXPERIMENTAL): This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).